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Table. The dots were smaller (~10 nm) and more
homogeneous (PDI~0.2), whereas SLNs of different
compositions were much larger (~120 nm) and more
heterogeneous (PDI~0.4). For miriplatin-loaded SLNs
with different compositions, the sizes decreased (from
195.00 nm to 22.81nm) as the percentage of 18:0 PE-PEG
increased (from 5% to 40%). The quantification of
miriplatin by ICP-OES have shown high platinum
recovery (>80%) in both ultrasmall dots and SLNs.
Figure1. The images by TEM displayed their sizes and
morphology that were consistent with the size and PDI
measurements by Zetasizer.
Figure2. The ultrasmall dots and selected SLNs showed
significantly stronger 3D MCS inhibition against 3D MCS
than free miriplatin, and similar anti-cancer activity to
cisplatin. Miriplatin-loaded SLNs with more PE-PEG had
higher anti-cancer activity.
The lipid-based nano-formulations 
may serve as a potent delivery system 
for miriplatin against non-small cell 
lung cancer (NSCLC).
The reported lipid-based nano formulations which carried appropriate physiochemical
properties represent a promising delivery system for miriplatin against NSCLC.
1. Preparation of Formulations: Ultrasmall dots and
various SLNs were prepared by film-hydration
2. Characterization of Formulations: Sizes and PDI of
formulations were measured by Zetasizer. A quantification
method of platinum recovery was established using
inductively coupled plasma-optical emission
spectrometry(ICP-OES). The images by transmission
electron microscopy (TEM) displayed the sizes and
morphology of formulations.
3. In-vitro Evaluation of Anti-cancer Activity against
NSCLC: A three-dimensional multicellular spheroid
model (3D MCS) of A549-iRFP cells was established.
During 7-day treatment, the fluorescent signal was
recorded and analyzed by Infrared Imaging System at the
700 nm channel. The cell viability was measured by UV
absorbance at 490 nm on microplate reader using 3D
viability Assay.
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1. Lung cancer claims the highest
mortality and the second-most new
cases among all oncological diseases.
NSCLC accounts for approximately
85% of all newly diagnosed lung
cancers.
2. Although platinum-based drugs are
recommended standard first-line
chemotherapy for stage IIIB/IV
NSCLC, accumulating reports have
shown failure of conventional
platinum-based regimens due to drug
resistance.
3. Miriplatin is a lipophilic anti-
cancer drug that has been approved in
Japan for transcatheter arterial
chemoembolization treatment of
hepatocellular carcinoma.
4. Lipid-based nanoparticles such as
liposomes, micelles, and solid lipid
nanoparticles (SLNs) can encapsulate
anti-cancer drugs to improve their
water solubility and bioavailability.
HYPOTHESIS
Lipid-based nano formulations of
miriplatin would carry appropriate
physiochemical properties to
improve the anticancer activity of
platinum drugs against NSCLC.
Lipid Compositions Drug input (molar%) Size(nm) PDI Pt Recovery
SLN: 95%TP/5%PE-PEG 10%Miriplatin 195.00 0.512 /
SLN: 95%TM/5%PE-PEG 10%Miriplatin 121.30 0.262 /
SLN: 90%TP/10%PE-PEG 10%Miriplatin 106.10 0.343 128.81%
SLN: 90%TM/10%PE-PEG 10%Miriplatin 57.34 0.856 94.78%
SLN: 80%TP/20%PE-PEG 10%Miriplatin 79.31 0.413 99.01%
SLN: 80%TM/20%PE-PEG 10%Miriplatin 131.40 0.217 101.07%
SLN: 60%TP/40%PE-PEG 10%Miriplatin 18.81 0.500 /
SLN: 60%TM/40%PE-PEG 10%Miriplatin 22.81 0.846 /
Micelle: 100%PE-PEG 10%Miriplatin 11.24 0.240 /
Micelle: 100%PE-PEG 20%Miriplatin 11.90 0.247 80.80%
Micelle: 100%PE-PEG 20%Miriplatin+10% Paclitaxel 11.71 0.254 77.70%
SLN: 90%TP/10%PE-PEG 20%Miriplatin 86.88 0.261 /
SLN: 90%TM/10%PE-PEG 20%Miriplatin+10% Paclitaxel 91.45 0.241 /
SLN: 60%TP/40%PE-PEG 20%Miriplatin 137.40 0.379 99.66%
SLN: 60%TM/40%PE-PEG 20%Miriplatin 158.50 0.135 100.98%
SLN: 60%TP/40%PE-PEG 20%Miriplatin+10% Paclitaxel 41.08 0.417 91.76%
SLN: 60%TM/40%PE-PEG 20%Miriplatin+10% Paclitaxel 94.55 0.868 57.29%
(TM: trimyristin, TP: tripalmitin, PE-PEG: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy (polyethylene glycol)-2000] (ammonium salt)) 
Table. Size, PDI and Pt Recovery of Miriplatin-Loaded Formulations 
(SLNs and dots) with Different Compositions 
Figure2. 3D MCS Viability% of formulations with different compositions 
based on 3D Viability Assay and Fluorescence signal (Mean ± S.D, N =3) 
Figure1. TEM images of 
miriplatin-loaded dots and SLNs. 
(a) Dots containing 100% PE-
PEG + 20% miriplatin.
(b) SLNs containing 60% TP/40% 
PE-PEG + 20% miriplatin.
(c) SLNs containing 60% TP/40% 
PE-PEG + 20% miriplatin+10% 
paclitaxel.
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